Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

atropine sulfate

ATROPINE INJECTION (BRIDGEWEST)

atropine sulfate (ATROPINE INJECTION (BRIDGEWEST)) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: intravenous, intramuscular, subcutaneous, intrao. Current US regulatory status: approved.

FDA: approved EMA: approved TGA: approved Sensory organs (S01) S01FA01
US status approved
Patents linked 20
Pipeline programs 76
News articles 0
Congress events 1
Drug details — atropine sulfate
US status
approved
Class
Sensory organs (S01)
Route
INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAO
Patents
20
Programs
76
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Congress events Drug news hub Event calendar

Quick answer

atropine sulfate (ATROPINE INJECTION (BRIDGEWEST)) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: intravenous, intramuscular, subcutaneous, intrao. Current US regulatory status: approved.

Key facts

INN atropine sulfate
Brand ATROPINE INJECTION (BRIDGEWEST)
Mechanism Muscarinic acetylcholine receptor M3 antagonist
Target Muscarinic acetylcholine receptor M1
Therapeutic class Sensory organs (S01)
Route INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAO
Formulation CAPSULE
ATC code S01FA01
Originator Lacuna Pharma Pty Ltd

Mechanism of action

Muscarinic acetylcholine receptor M3 antagonist

Primary target: Muscarinic acetylcholine receptor M1

Approval history

Authority Status Date
FDA approved —
EMA approved —
TGA approved —

Congress & event coverage

Browse event calendar
  • Presentation
    ASCO 2026

    1 presentation · oncology

Pipeline programs

Search pipeline Sponsor programs
  1. APHP210089 Phase 3 · PARItec · Patients hospitalized for allogeneic hematopoietic stem cell
  2. ASCIMINIB HYDROCHLORIDE, ASCIMINIB Phase 3 · Novartis India · Chronic Myelogenous Leukemia in chronic phase (CML-CP)
  3. Asciminib Phase 3 · Novartis India · Chronic Myelogenous Leukemia
  4. Atropine sulfate eye drops 0.01% Phase 3 · Chinese Academy of · Myopia
  5. CABL001A2001B Phase 3 · Novartis India · chronic myelogenous leukemia (CML) or Philadelphia Chromosom
  6. CD101.IV.3.08 Phase 3 · Mundipharma · Invasive Fungal Diseases in Adults undergoing Allogeneic Blo
  7. CLS2901C (human [allogeneic] chondrocyte sheets) Phase 3 · CellSeed Europe · Osteoarthritis of the Knee
  8. Pegylated Interferon Alfa-2a Phase 3 · HOFFMANN-LA ROCHE · Chronic Myelogenous Leukemia

Related & competitor drugs

Browse all drugs
  1. aflibercept Sensory organs (S01)
  2. benztropine mesylate Muscarinic acetylcholine receptor M1 antagonist
  3. bimatoprost Sensory organs (S01)
  4. dicyclomine hydrochloride Muscarinic acetylcholine receptor M3 antagonist
  5. glycopyrrolate Muscarinic acetylcholine receptor M3 antagonist
  6. pilocarpine hydrochloride Muscarinic acetylcholine receptor M3 agonist

Related patents

Browse patents Lacuna Pharma Pty Ltd patent hub

  1. US 12377068

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12357650

    Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation

    Expires Mon Jul 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12252714

    Halogenation of complex organic compounds

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12247226

    Cellular reprogramming using temporal and transient plasmid vector expression system

    Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12221462

    Methods and compositions for dosing of allogeneic chimeric antigen receptor T cells

    Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12163153

    Methods of manufacturing allogeneic CAR T cells

    Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12138276

    Halogenated psilocybin derivatives and methods of using

    Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12133840

    Halogenated xanthene composition and method for treating hematologic cancers

    Expires Mon Oct 31 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12070460

    Methods of treating skin cancer with Carboxypeptidase Vitellogenic Like (CPVL) inhibitors

    Expires Mon Aug 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11998557

    Halogenated psilocybin derivatives and methods of using

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11974980

    In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11975106

    Uses of halogenated xanthenes in oncology and virology

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11938182

    Halogenated xanthenes as vaccine adjuvants

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 11826405

    Neurotoxin compositions for use in treating headache

    Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 11696898

    Halogenated ether compounds and methods of inducing anesthesia

    Expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11692176

    Halogenation of complex organic compounds

    Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11654157

    Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorylase inhibitors in combination with radiation

    Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11419844

    Halogenated xanthene composition and method for treating hematologic cancers

    Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11389481

    Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19

    Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11351276

    Radiopharmaceutical compositions of radioactive halogenated benzylguanidine

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is atropine sulfate?

atropine sulfate (ATROPINE INJECTION (BRIDGEWEST)) is a muscarinic acetylcholine receptor m3 antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: intravenous, intramuscular, subcutaneous, intrao. Current US regulatory status: approved.

What is the brand name for atropine sulfate?

ATROPINE INJECTION (BRIDGEWEST) is a marketed brand name for atropine sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of atropine sulfate?

atropine sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.